Ulland Investment Advisors LLC Sells 920 Shares of Boston Scientific Co. (NYSE:BSX)

Ulland Investment Advisors LLC cut its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 5.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,599 shares of the medical equipment provider’s stock after selling 920 shares during the period. Boston Scientific makes up approximately 1.2% of Ulland Investment Advisors LLC’s investment portfolio, making the stock its 22nd largest holding. Ulland Investment Advisors LLC’s holdings in Boston Scientific were worth $1,473,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BSX. TFC Financial Management Inc. raised its stake in shares of Boston Scientific by 308.8% in the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 210 shares during the period. Colonial Trust Co SC increased its position in Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 260 shares during the last quarter. Investment Management Corp VA ADV acquired a new position in Boston Scientific during the fourth quarter worth approximately $25,000. Sunbeam Capital Management LLC acquired a new position in Boston Scientific during the fourth quarter worth approximately $26,000. Finally, Ameriflex Group Inc. acquired a new position in Boston Scientific during the fourth quarter worth approximately $31,000. 89.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Morgan Stanley upped their target price on Boston Scientific from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Friday, May 16th. Citigroup reiterated a “buy” rating and issued a $125.00 price target (up from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Erste Group Bank upgraded Boston Scientific to a “strong-buy” rating in a research note on Thursday, May 8th. Truist Financial boosted their price target on Boston Scientific from $113.00 to $117.00 and gave the company a “buy” rating in a research note on Thursday, April 24th. Finally, Evercore ISI upped their target price on Boston Scientific from $110.00 to $112.00 and gave the stock an “outperform” rating in a research note on Thursday, April 24th. Twenty-one investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $116.00.

Boston Scientific Price Performance

Boston Scientific stock opened at $99.38 on Thursday. The business has a fifty day moving average price of $100.70 and a 200-day moving average price of $98.55. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a one year low of $71.88 and a one year high of $107.17. The firm has a market capitalization of $147.03 billion, a P/E ratio of 79.50, a PEG ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm had revenue of $4.66 billion for the quarter, compared to analysts’ expectations of $4.57 billion. During the same quarter in the previous year, the company earned $0.56 earnings per share. The company’s revenue for the quarter was up 20.9% compared to the same quarter last year. As a group, equities research analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, SVP Vance R. Brown sold 4,826 shares of Boston Scientific stock in a transaction on Monday, April 21st. The shares were sold at an average price of $95.09, for a total value of $458,904.34. Following the completion of the transaction, the senior vice president now directly owns 36,193 shares of the company’s stock, valued at $3,441,592.37. This trade represents a 11.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP John Bradley Sorenson sold 4,572 shares of Boston Scientific stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $104.54, for a total transaction of $477,956.88. Following the transaction, the executive vice president now directly owns 18,705 shares of the company’s stock, valued at approximately $1,955,420.70. This represents a 19.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 411,970 shares of company stock valued at $42,406,693. Insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.